Connection

FENG YANG to Humans

This is a "connection" page, showing publications FENG YANG has written about Humans.
Connection Strength

0.206
  1. Cooperative activation of PDK1 and AKT by MAPK4 enhances cancer growth and resistance to therapy. PLoS Biol. 2023 08; 21(8):e3002227.
    View in: PubMed
    Score: 0.024
  2. A COP1-GATA2 axis suppresses AR signaling and prostate cancer. Proc Natl Acad Sci U S A. 2022 10 25; 119(43):e2205350119.
    View in: PubMed
    Score: 0.023
  3. MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nat Commun. 2022 01 11; 13(1):245.
    View in: PubMed
    Score: 0.022
  4. SPINDOC binds PARP1 to facilitate PARylation. Nat Commun. 2021 11 04; 12(1):6362.
    View in: PubMed
    Score: 0.021
  5. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest. 2021 02 15; 131(4).
    View in: PubMed
    Score: 0.020
  6. Avian Retrovirus-Mediated Tumor-Specific Gene Knockout. Curr Protoc Mol Biol. 2018 01 16; 121:23.17.1-23.17.7.
    View in: PubMed
    Score: 0.016
  7. A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis. Neoplasia. 2017 May; 19(5):421-428.
    View in: PubMed
    Score: 0.015
  8. Stromal TGF-? signaling induces AR activation in prostate cancer. Oncotarget. 2014 Nov 15; 5(21):10854-69.
    View in: PubMed
    Score: 0.013
  9. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene. 2008 Jan 17; 27(4):450-9.
    View in: PubMed
    Score: 0.008
  10. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005 Oct 01; 65(19):8887-95.
    View in: PubMed
    Score: 0.007
  11. TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2023 05 16; 120(20):e2218229120.
    View in: PubMed
    Score: 0.006
  12. The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy. Front Immunol. 2021; 12:625667.
    View in: PubMed
    Score: 0.005
  13. The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies. Front Immunol. 2021; 12:625783.
    View in: PubMed
    Score: 0.005
  14. SENP1 regulates PTEN stability to dictate prostate cancer development. Oncotarget. 2017 Mar 14; 8(11):17651-17664.
    View in: PubMed
    Score: 0.004
  15. Activating CAR and ?-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun. 2015 Feb 09; 6:5944.
    View in: PubMed
    Score: 0.003
  16. RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation. Proc Natl Acad Sci U S A. 2014 Nov 18; 111(46):16389-94.
    View in: PubMed
    Score: 0.003
  17. WFDC1 is a key modulator of inflammatory and wound repair responses. Am J Pathol. 2014 Nov; 184(11):2951-64.
    View in: PubMed
    Score: 0.003
  18. TGF-?1 induces an age-dependent inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse. PLoS One. 2010 Oct 29; 5(10):e13751.
    View in: PubMed
    Score: 0.002
  19. WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection. J Virol. 2008 Jan; 82(1):471-86.
    View in: PubMed
    Score: 0.002
  20. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res. 2003 Sep 15; 63(18):5859-65.
    View in: PubMed
    Score: 0.002
  21. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 2002 Nov 01; 62(21):6021-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.